Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2025
Reporting Period: Single event date (October 30, 2025)
Business Context: The registrant is a clinical-stage biotechnology company focused on heart failure treatments. This filing reports a specific milestone in its ongoing clinical development program.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing is strictly an event report regarding clinical trial progress.
Material Changes
Clinical Trial Milestone: On October 30, 2025, BioCardia, Inc. announced the enrollment of the first patient in its Phase 3 CardiAMP HF II clinical trial.
Location: The enrollment occurred at the University of Wisconsin School of Medicine and Public Health.
Comparison: No prior period financial or operational data is provided in this document to establish a comparative change.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the patient enrollment. No forward-looking financial guidance or specific outlook statements are included in the text of this 8-K.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information furnished in Item 8.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial design and enrollment targets.
- Confirm the status of other sites in the Phase 3 CardiAMP HF II trial to assess overall enrollment velocity.
- Review recent 10-Q or 10-K filings for the company's current cash runway and burn rate, as this 8-K does not provide liquidity data.
- Monitor subsequent filings for updates on patient enrollment rates and any potential delays in the trial timeline.